Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising ...

Polycythemia vera is not hereditary. While it results from a genetic mutation, or a change in the DNA in a bone marrow cell, the change usually develops during life.

Panelists discuss how rusfertide, a hepcidin mimetic peptide, shows promise in polycythemia vera by reducing phlebotomy ...

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

CURRENTLY, polycythemia vera is considered by most hematologists to fall in the category of myeloproliferative disorders, a classification that also includes chronic myelocytic leukemia, erythremic ...

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, Protagonist Therapeutics and Takeda Pharmaceutical Company Limited (NYSE:TAK) ...

Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin ...

Dr. Aaron Gerds breaks down the outcomes of the phase 3 VERIFY trial, investigating rusfertide, for patients with polycythemia vera, a type of blood cancer.